Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Mx1 in Hematopoietic Cells Protects against Thogoto Virus Infection.

Spitaels J, Van Hoecke L, Roose K, Kochs G, Saelens X.

J Virol. 2019 Jul 17;93(15). pii: e00193-19. doi: 10.1128/JVI.00193-19. Print 2019 Aug 1.

PMID:
31092574
2.

How mRNA therapeutics are entering the monoclonal antibody field.

Van Hoecke L, Roose K.

J Transl Med. 2019 Feb 22;17(1):54. doi: 10.1186/s12967-019-1804-8. Review.

3.

Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes.

Van Hoecke L, Van Lint S, Roose K, Van Parys A, Vandenabeele P, Grooten J, Tavernier J, De Koker S, Saelens X.

Nat Commun. 2018 Aug 24;9(1):3417. doi: 10.1038/s41467-018-05979-8.

4.

Removal of the N-Glycosylation Sequon at Position N116 Located in p27 of the Respiratory Syncytial Virus Fusion Protein Elicits Enhanced Antibody Responses after DNA Immunization.

Leemans A, Boeren M, Van der Gucht W, Pintelon I, Roose K, Schepens B, Saelens X, Bailey D, Martinet W, Caljon G, Maes L, Cos P, Delputte P.

Viruses. 2018 Aug 14;10(8). pii: E426. doi: 10.3390/v10080426.

5.

Antibodies Directed toward Neuraminidase N1 Control Disease in a Mouse Model of Influenza.

Job ER, Schotsaert M, Ibañez LI, Smet A, Ysenbaert T, Roose K, Dai M, de Haan CAM, Kleanthous H, Vogel TU, Saelens X.

J Virol. 2018 Jan 30;92(4). pii: e01584-17. doi: 10.1128/JVI.01584-17. Print 2018 Feb 15.

6.

Oral delivery of Escherichia coli persistently infected with M2e-displaying bacteriophages partially protects against influenza A virus.

Deng L, Roose K, Job ER, De Rycke R, Van Hamme E, Gonçalves A, Parthoens E, Cicchelero L, Sanders N, Fiers W, Saelens X.

J Control Release. 2017 Oct 28;264:55-65. doi: 10.1016/j.jconrel.2017.08.020. Epub 2017 Aug 24.

PMID:
28842314
7.

Inflammatory monocytes regulate Th1 oriented immunity to CpG adjuvanted protein vaccines through production of IL-12.

De Koker S, Van Hoecke L, De Beuckelaer A, Roose K, Deswarte K, Willart MA, Bogaert P, Naessens T, De Geest BG, Saelens X, Lambrecht BN, Grooten J.

Sci Rep. 2017 Jul 20;7(1):5986. doi: 10.1038/s41598-017-06236-6.

8.

Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration.

Van Hoecke L, Job ER, Saelens X, Roose K.

J Vis Exp. 2017 May 4;(123). doi: 10.3791/55398.

9.

Arginine-Rich Peptide-Based mRNA Nanocomplexes Efficiently Instigate Cytotoxic T Cell Immunity Dependent on the Amphipathic Organization of the Peptide.

Udhayakumar VK, De Beuckelaer A, McCaffrey J, McCrudden CM, Kirschman JL, Vanover D, Van Hoecke L, Roose K, Deswarte K, De Geest BG, Lienenklaus S, Santangelo PJ, Grooten J, McCarthy HO, De Koker S.

Adv Healthc Mater. 2017 Jul;6(13). doi: 10.1002/adhm.201601412. Epub 2017 Apr 24.

PMID:
28436620
10.

Bispecific T cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.

Pendzialek J, Roose K, Smet A, Schepens B, Kufer P, Raum T, Baeuerle PA, Muenz M, Saelens X, Fiers W.

Antiviral Res. 2017 May;141:155-164. doi: 10.1016/j.antiviral.2017.02.016. Epub 2017 Mar 1.

PMID:
28257797
11.

Hierarchical and Redundant Roles of Activating FcγRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies.

Van den Hoecke S, Ehrhardt K, Kolpe A, El Bakkouri K, Deng L, Grootaert H, Schoonooghe S, Smet A, Bentahir M, Roose K, Schotsaert M, Schepens B, Callewaert N, Nimmerjahn F, Staeheli P, Hengel H, Saelens X.

J Virol. 2017 Mar 13;91(7). pii: e02500-16. doi: 10.1128/JVI.02500-16. Print 2017 Apr 1.

12.

Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.

Altenburg AF, van de Sandt CE, van Trierum SE, De Gruyter HLM, van Run PRWA, Fouchier RAM, Roose K, Saelens X, Volz A, Sutter G, de Vries RD, Rimmelzwaan GF.

J Virol. 2016 Oct 28;90(22):10209-10219. doi: 10.1128/JVI.01633-16. Print 2016 Nov 15.

13.

Influenza and Memory T Cells: How to Awake the Force.

Spitaels J, Roose K, Saelens X.

Vaccines (Basel). 2016 Oct 13;4(4). pii: E33. Review.

14.

Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.

De Beuckelaer A, Pollard C, Van Lint S, Roose K, Van Hoecke L, Naessens T, Udhayakumar VK, Smet M, Sanders N, Lienenklaus S, Saelens X, Weiss S, Vanham G, Grooten J, De Koker S.

Mol Ther. 2016 Nov;24(11):2012-2020. doi: 10.1038/mt.2016.161. Epub 2016 Aug 10.

15.

A20 Deficiency in Lung Epithelial Cells Protects against Influenza A Virus Infection.

Maelfait J, Roose K, Vereecke L, Mc Guire C, Sze M, Schuijs MJ, Willart M, Ibañez LI, Hammad H, Lambrecht BN, Beyaert R, Saelens X, van Loo G.

PLoS Pathog. 2016 Jan 27;12(1):e1005410. doi: 10.1371/journal.ppat.1005410. eCollection 2016 Jan.

16.

Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages.

Deng L, Ibañez LI, Van den Bossche V, Roose K, Youssef SA, de Bruin A, Fiers W, Saelens X.

PLoS One. 2015 May 14;10(5):e0126650. doi: 10.1371/journal.pone.0126650. eCollection 2015.

17.

A GFP expressing influenza A virus to report in vivo tropism and protection by a matrix protein 2 ectodomain-specific monoclonal antibody.

De Baets S, Verhelst J, Van den Hoecke S, Smet A, Schotsaert M, Job ER, Roose K, Schepens B, Fiers W, Saelens X.

PLoS One. 2015 Mar 27;10(3):e0121491. doi: 10.1371/journal.pone.0121491. eCollection 2015.

18.

Structure of the extracellular domain of matrix protein 2 of influenza A virus in complex with a protective monoclonal antibody.

Cho KJ, Schepens B, Seok JH, Kim S, Roose K, Lee JH, Gallardo R, Van Hamme E, Schymkowitz J, Rousseau F, Fiers W, Saelens X, Kim KH.

J Virol. 2015 Apr;89(7):3700-11. doi: 10.1128/JVI.02576-14. Epub 2015 Jan 21.

19.

Sequence-dependent internalization of aggregating peptides.

Couceiro JR, Gallardo R, De Smet F, De Baets G, Baatsen P, Annaert W, Roose K, Saelens X, Schymkowitz J, Rousseau F.

J Biol Chem. 2015 Jan 2;290(1):242-58. doi: 10.1074/jbc.M114.586636. Epub 2014 Nov 12.

20.

Protection and mechanism of action of a novel human respiratory syncytial virus vaccine candidate based on the extracellular domain of small hydrophobic protein.

Schepens B, Sedeyn K, Vande Ginste L, De Baets S, Schotsaert M, Roose K, Houspie L, Van Ranst M, Gilbert B, van Rooijen N, Fiers W, Piedra P, Saelens X.

EMBO Mol Med. 2014 Nov;6(11):1436-54. doi: 10.15252/emmm.201404005.

21.

Influenza vaccines to control influenza-associated bacterial infection: where do we stand?

Christopoulou I, Roose K, Ibañez LI, Saelens X.

Expert Rev Vaccines. 2015 Jan;14(1):55-67. doi: 10.1586/14760584.2015.957191. Epub 2014 Sep 11. Review.

PMID:
25209381
22.

Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.

Cardoso FM, Ibañez LI, Van den Hoecke S, De Baets S, Smet A, Roose K, Schepens B, Descamps FJ, Fiers W, Muyldermans S, Depicker A, Saelens X.

J Virol. 2014 Aug;88(15):8278-96. doi: 10.1128/JVI.03178-13. Epub 2014 May 14.

23.

M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A.

Ibañez LI, Roose K, De Filette M, Schotsaert M, De Sloovere J, Roels S, Pollard C, Schepens B, Grooten J, Fiers W, Saelens X.

PLoS One. 2013;8(3):e59081. doi: 10.1371/journal.pone.0059081. Epub 2013 Mar 18.

24.

Hepatitis B core-based virus-like particles to present heterologous epitopes.

Roose K, De Baets S, Schepens B, Saelens X.

Expert Rev Vaccines. 2013 Feb;12(2):183-98. doi: 10.1586/erv.12.150. Review.

PMID:
23414409
25.

Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice.

De Baets S, Schepens B, Sedeyn K, Schotsaert M, Roose K, Bogaert P, Fiers W, Saelens X.

J Virol. 2013 Mar;87(6):3314-23. doi: 10.1128/JVI.03019-12. Epub 2013 Jan 9.

26.

A20 (Tnfaip3) deficiency in myeloid cells protects against influenza A virus infection.

Maelfait J, Roose K, Bogaert P, Sze M, Saelens X, Pasparakis M, Carpentier I, van Loo G, Beyaert R.

PLoS Pathog. 2012;8(3):e1002570. doi: 10.1371/journal.ppat.1002570. Epub 2012 Mar 1. Erratum in: PLoS Pathog. 2012 Apr;8(4): doi/10.1371/annotation/a2136b9a-3cbf-426f-9cfb-73e3c9c6396d.

27.

Antiserum against the conserved nine amino acid N-terminal peptide of influenza A virus matrix protein 2 is not immunoprotective.

De Filette M, Ysenbaert T, Roose K, Schotsaert M, Roels S, Goossens E, Schepens B, Fiers W, Saelens X.

J Gen Virol. 2011 Feb;92(Pt 2):301-6. doi: 10.1099/vir.0.027086-0. Epub 2010 Oct 21.

PMID:
20965983
28.

M2e-based universal influenza A vaccine.

Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Birkett A, Saelens X.

Vaccine. 2009 Oct 23;27(45):6280-3. doi: 10.1016/j.vaccine.2009.07.007. Review.

PMID:
19840661
29.

Pandemic preparedness: toward a universal influenza vaccine.

Roose K, Fiers W, Saelens X.

Drug News Perspect. 2009 Mar;22(2):80-92. doi: 10.1358/dnp.2009.22.2.1334451. Review.

PMID:
19330167
30.

An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

De Filette M, Martens W, Roose K, Deroo T, Vervalle F, Bentahir M, Vandekerckhove J, Fiers W, Saelens X.

J Biol Chem. 2008 Apr 25;283(17):11382-7. doi: 10.1074/jbc.M800650200. Epub 2008 Feb 5.

31.

Carbohydrate supplementation of horses during endurance exercise: comparison of fructose and glucose.

Bullimore SR, Pagan JD, Harris PA, Hoekstra KE, Roose KA, Gardner SC, Geor RJ.

J Nutr. 2000 Jul;130(7):1760-5.

PMID:
10867047
32.

Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration.

Roose K, Gelders Y, Heylen S.

Acta Psychiatr Belg. 1988 May-Jun;88(3):233-41.

PMID:
2466393

Supplemental Content

Support Center